Cardiac allograft vasculopathy: Differences in de novo and maintenance heart transplant recipients

Transplantation

Volumn 82, Issue 8 SUPPL., 2006, Pages

  Frigerio, Maria ^a   Garascia, Andrea ^a   Roubina, Elena ^a   Distefano, Giada ^a   Orrego, Pedro Silva ^a   Colombo, Paola ^a   Bruschi, Giuseppe ^a   Vitali, Ettore ^a  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

Author keywords

Cardiac allograft vasculopathy; Everolimus; Heart transplantation; Immunosuppression; Late complications; Proliferation signal inhibitors mTOR inhibitors

Indexed keywords

EVEROLIMUS; RAPAMYCIN;

ANGIOCARDIOGRAPHY; ARTICLE; CARDIAC ALLOGRAFT VASCULOPATHY; CELL PROLIFERATION; FOLLOW UP; HEART FUNCTION; HEART PERFUSION; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAVASCULAR ULTRASOUND; LONG TERM CARE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; REVASCULARIZATION; SCINTIGRAPHY; STRESS ECHOCARDIOGRAPHY;

EID: 33750323563     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000243150.89762.fc     Document Type: Article

References (67)

1. Taylor DO, Edwards LB, Boucek MM, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-second official adult heart transplant report - 2005. J Heart Lung Transplant 2005; 24: 945.
2. Ramzy D, Rao V, Brahm J, Miriuka S, Delgado D, Ross HJ. Cardiac allograft vasculopathy: a review. Can J Surg 2005; 48: 319.
3. Kass M, Haddad H. Cardiac allograft vasculopathy: pathology, prevention and treatment. Curr Opin Cardiol 2006; 21: 132.
4. Beckers F, Ramaekers D, Speijer G, et al. Different evolutions in heart rate variability after heart transplantation: 10-year follow-up. Transplantation 2004; 78: 1523.
5. Bengel FM, Ueberfuhr P, Hesse T, et al. Clinical determinants of ventricular sympathetic reinnervation after orthotopic heart transplantation. Circulation 2002; 106: 831.
6. Bengel FM, Ueberfuhr P Schiepel N, et al. Effect of sympathetic reinnervation on cardiac performance after heart transplantation. N Engl J Med 2001; 345: 731.
7. Gao SZ, Alderman E, Schroeder J, Silverman JF. Accelerated coronary vascular disease in the heart transplant patient: coronary arteriographic findings. J Am Coll Cardiol 1988; 12: 334.
8. Schoenhagen P, Ziada KM, Vince DG, et al. Arterial remodeling and coronary artery disease: the concept of "dilated" versus "obstructive" coronary atherosclerosis. J Am Coll Cardiol 2001; 38: 297.
9. Sharples LD, Jackson CH, Parameshwar J, Wallwork J, Large SR. Diagnostic accuracy of coronary angiography and risk factors for post-heart transplant cardiac allograft vasculopathy. Transplantation 2003; 76: 679.
10. Syeda B, Roedlerb S, Schukroa, et al. Transplant coronary artery disease: Incidence, progression and interventional revascularization. Int J Cardiol 2005; 104: 269.
11. Luyt CE, Drobinski G, Dorent R, et al. Prognosis of moderate coronary artery lesions in heart transplant patients. J Heart Lung Transplant 2003; 22: 130.
12. Caforio ALP, Tona F, Belloni Fortina A, et al. Immune and nonimmune predictors of cardiac allograft vasculopathy onset and severity: multivariate risk factors analysis and role of immunosuppression. Am J Transplant 2004; 4: 962.
13. Clague JR, Cox ID, Murday AJ, et al. Low clinical utility of angiographic surveillance in the detection and management of cardiac allograft vasculopathy in transplant recipients. Clin Cardiol 2001; 24: 459.
14. Sechtem U. Do heart transplant recipients need annual coronary angiography? Eur Heart J 2001; 22: 895.
15. Aranda JM, Hill J. Cardiac transplant vasculopathy. Chest 2000; 118: 1792.
16. Nissen SE. Application of intravascular ultrasound to characterize coronary artery disease and assess the progression or regression of atherosclerosis. Am J Cardiol 2002; 89 (Suppl): 24B.
17. Rickenbacher PR, Pinto FJ, Lewis NP, et al. Prognostic importance of intimal thickness as measured by intracoronary ultrasound after cardiac transplantation. Circulation 1995; 92: 3445.
18. Kobashigawa JA. First-year intravascular ultrasound results as a surrogate marker for outcomes after heart transplantation. J Heart Lung Transplant 2003; 22: 711.
19. Mehra MR, Ventura HO, Stapleton DD, et al. Presence of severe intimal thickening by intravascular ultrasonography predicts cardiac events in cardiac allograft vasculopathy. J Heart Lung Transplant 1995; 14: 632.
20. Kobashigawa JA, Tobis JM, Starling RC, et al. Multicenter intravascular ultrasound validation study among heart transplant recipients: outcomes after five years. J Am Coll Cardiol 2005; 45: 1532.
21. Tuzcu EM, Kapadia SR, Tutar E, et al. High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults: evidence from intravascular ultrasound. Circulation 2001; 103: 2705.
22. Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac transplant recipients. N Engl J Med 2003; 349: 847.
23. Keogh A, Richardson M, Ruygrok P, et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years. A randomized clinical trial. Circulation 2004; 110: 10.
24. Kobashigawa JA, Meiser BM. Review of major clinical trials with mycophenolate mofetil in cardiac transplantation. Transplantation 2005; 80(Suppl 2): 235.
25. Hollenberg SM, Klein LW, Parrillo JE, et al. Coronary endothelial dysfunction after heart transplantation predicts allograft vasculopathy and cardiac death. Circulation 2001; 104: 3091.
26. Fearon WF, Nakamura M, Lee DP, et al. Simultaneous assessment of fractional and coronary flow reserves in cardiac transplant recipients physiologic investigation for transplant arteriopathy (PITA Study). Circulation 2003; 108: 1605.
27. Potluri SP, Mehra MR, Uber PA, Park MH, Scott RL, Ventura HO. Relationship among epicardial coronary disease, tissue myocardial perfusion, and survival in heart transplantation. J Heart Lung Transplant 2005; 24: 1019.
28. Romeo G, Houyel L, Angel C-Y, et al. Coronary stenosis detection by 16-slice computed tomography in heart transplant patients: comparison with conventional angiography and impact on clinical management. J Am Coll Cardiol 2005; 45: 1826.
29. Bacal F, Moreira LF, Souza G, Rodrigues AC. Dobutamine stress echocardiography predicts cardiac events or death in asymptomatic patients long-term after heart transplantation: 4-year prospective evaluation. J Heart Lung Transplant 2004; 23: 1238.
30. Carlsen J, Toft JC, Mortensen SA, et al. Myocardial perfusion scintigraphy as a screening method for significant coronary artery stenosis in cardiac transplant recipients. J Heart Lung Transplant 2000; 19: 873.
31. Ciliberto GR, Parodi O, Cataldo G, et al. Prognostic value of contractile response during high-dose dipyridamole echocardiography test in heart transplant recipients. J Heart Lung Transplant 2003; 22: 526.
32. Hacker M, Tausig A, Romuller B, et al. Dobutamine myocardial scintigraphy for the prediction of cardiac events after heart transplantation. Nucl Med Commun 2005; 26: 607.
33. Ciliberto GR, Ruffini L, Mangiavacchi M, et al. Resting echocardiography and quantitative dipyridamole technetium-99m sestamibi tomography in the identification of cardiac allograft vasculopathy and the prediction of long-term prognosis after heart transplantation. Eur Heart J 2001; 22: 964.
34. Wu Y-W, Yen R-F, Lee C-M, et al. Diagnostic and prognostic value of dobutamine thallium-201 single-photon emission computed tomography after heart transplantation. J Heart Lung Transplant 2005; 24: 544.
35. Derumeaux G, Redonnet M, Soyer R, et al. Assessment of the progression of cardiac allograft vasculopathy by dobutamine stress echocardiography. J Heart Lung Transplant 1998; 17: 259.
36. Spes CH, Klauss V, Mudra H, et al. Diagnostic and prognostic value of serial dobutamine stress echocardiography for noninvasive assessment of cardiac allograft vasculopathy. A comparison with coronary angiography and intravascular ultrasound. Circulation 1999; 100: 509.
37. Labarrere CA, Lee JB, Nelson DR, Al-Hassani M, Miller SJ, Pitts DE. C-reactive protein, arterial endothelial activation, and development of transplant coronary artery disease: a prospective study. Lancet 2002; 360: 1462.
38. Yousufuddina M, Hajib S, Starling RC, et al. Cardiac angiotensin II receptors as predictors of transplant coronary artery disease following heart transplantation. Eur Heart J 2004; 25: 377.
39. Weis M, Kledal TN, Lin KY, et al. Cytomegalovirus infection impairs the nitric oxide synthase pathway role of asymmetric dimethylarginine in transplant arteriosclerosis. Circulation 2004; 109: 500.
40. Tanaka M, Sydow K, Gunawan BA, et al. Dimethylarginine dimethylaminohydrolase overexpression suppresses graft coronary artery disease. Circulation 2005; 112: 1549.
41. Costanzo MR, Naftel DC, Pritzker MR, et al. for the Cardiac Transplant Research Database. Heart transplant coronary artery disease detected by coronary angiography: a multiinstitutional study of preoperative donor and recipient risk factors. J Heart Lung Transplant 1998; 17: 744.
42. Kobashigawa J, Wener L, Johnson J, et al. Longitudinal study of vascular remodeling in coronary arteries after heart transplantation. J Heart Lung Transplant 2000; 19: 546.
43. Kapadia SR, Nissen SE, Tuzcu EM. Impact of intravascular ultrasound in understanding transplant coronary artery disease. Curr Opin Cardiol 1999; 14: 140.
44. Mehra MR, Ventura HO, Uber PA, Scott RL, Park MH. Is all intimal proliferation created equal in cardiac allograft vasculopathy? The quantity-quality paradox. J Heart Lung Transplant 2003; 22: 118.
45. Mehra MR, Benza R, Deng MC, Russell S, Webber S. Surrogate markers for late cardiac allograft survival. Am J Transplant 2004; 4: 1184.
46. Eisen H, Starling RC, Kobashigawa J. Incidence of MACE and economic burden in de novo heart transplant patients: a 4 year comparison of everolimus and azathioprine. Transpl Int 2005; 18 (Suppl 1): PO111.
47. Elhendy A, van Domburg RT, Vantrimpont P, et al. Prediction of mortality in heart transplant recipients by stress technetium-99m tetrofosmin myocardial perfusion imaging. Am J Cardiol 2002; 89: 964.
48. Yamani MH, Yousufuddin M, Starling RC, et al. Does acute cellular rejection correlate with cardiac allograft vasculopathy? J Heart Lung Transplant 2004; 23: 272.
49. Anyanwu AC, Banner NR, Mitchell AG, Khaghani A, Yacoub MH. Low incidence and severity of transplant-associated coronary artery disease in heart transplants from live donors. J Heart Lung Transplant 2003; 22: 281.
50. Walker AH, Fildes JE, Leonard CT, Yonan N. The influence of donor age on transplant coronary artery disease and survival post heart transplantation: is it safe to extend donor age. Transplant Proc 2004; 36: 3139.
51. Morice M-C, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Eng J Med 2002; 346: 1773.
52. Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995; 333: 621.
53. Wenke K, Meiser B, Thiery J, et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial. Circulation 1997; 96: 1398.
54. de Denus S, Al-Jazairi A, Loh E, Jessup M, Stanek EJ, Spinler SA. Dyslipidemias and HMG-CoA reductase inhibitor prescription in heart transplant recipients. Ann Pharmacother 2004; 38: 1136.
55. Muscia M, Pasica M, Meyera R, et al. Coronary artery bypass grafting after orthotopic heart transplantation. Eur J Cardiothorac Surg 1999; 16: 163.
56. Patel VS, Radovancevic B, Springer W, et al. Revascularization procedures in patients with transplant coronary artery disease. Eur J Cardiothorac Surg 1997; 11: 895.
57. Halle AA, DiSciascio G, Massin EK, et al. Coronary angioplasty, atherectomy and bypass surgery in cardiac transplant recipients. J Am Coll Cardiol 1995; 26: 120.
58. Musci M, Loebe M, Wellnhofer E, et al. Coronary angioplasty, bypass surgery, and retransplantation in cardiac transplant patients with graft coronary disease. Thorac Cardiovasc Surg 1998; 46: 268.
59. Redonnet M, Tron C, Koning R, et al. Coronary angioplasty and stenting in cardiac allograft vasculopathy following heart transplantation. Transplant Proc 2000; 32: 463.
60. Schnetzler B, Drobinski G, Dorent R, et al. The role of percutaneous transluminal coronary angioplasty in heart transplant recipients. J Heart Lung Transplant 2000; 19: 557.
61. Aranda JM, Pauly DF, Kerensky RA, et al. Percutaneous coronary intervention versus medical therapy for coronary allograft vasculopathy. One center's experience. J Heart Lung Transplant 2002; 21: 860.
62. Fernández-Yáñez J, Palomo J, Elízaga A, Morena J, Sánchez A, Almendral J. Results of percutaneous revascularization in cardiac allograft vascular disease. Transplant Proc 2003; 35: 1996.
63. Benza RL, Zoghbi GJ, Tallaj J, et al. Palliation of allograft vasculopathy with transluminal angioplasty. J Am Coll Cardiol 2004; 43: 1973.
64. Doshi AA, Rogers J, Kern MJ, Hauptman PJ. Effectiveness of percutaneous coronary intervention in cardiac allograft vasculopathy. Am J Cardiol 2004; 93: 90.
65. Bader FM, Kfoury AG, Gilbert EM, et al. Percutaneous coronary interventions with stents in cardiac transplant recipients. J Heart and Lung Transplant 2006; 25: 298.
66. Mehra MR, Ventura HO, Chambers RB, et al. The prognostic impact of immunosuppression and cellular rejection on cardiac allograft vasculopathy: time for a reappraisal. J Heart Lung Transplant 1997; 16: 743.
67. Mancini D, Pinney S, Burkhoff D, et al. Use of rapamycin slows progression of cardiac transplant vasculopathy. Circulation 2003; 107: 48.